Published • loading... • Updated
Eli Lilly vs Novo Nordisk: The Battle for Obesity Drug Supremacy
Summary by 247wallst.com
1 Articles
1 Articles
Eli Lilly vs Novo Nordisk: The Battle for Obesity Drug Supremacy
Eli Lilly (NYSE: LLY | LLY Price Prediction) and Novo Nordisk (NYSE: NVO) reported Q1 2026 results that pulled the GLP-1 duopoly apart. Lilly grew revenue 55.5% and raised guidance. Novo posted a 4% adjusted sales decline at constant currency and is cutting 9,000 jobs. Both call obesity the prize, but their quarters tell very ... Eli Lilly vs Novo Nordisk: The Battle for Obesity Drug Supremacy
·New York, United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
